Umeclidinium Bromide Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

It is formulated by 2 pharmaceutical companies such as GLAXOSMITHKLINE, GLAXO GRP ENGLAND. It is marketed under 3 brand names, including ANORO ELLIPTA, INCRUSE ELLIPTA, TRELEGY ELLIPTA. Available in 4 different strengths, such as EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH, EQ 0.0625MG BASE/INH, 0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH and others, and administered through 1 route including POWDER;INHALATION.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 2 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"40458","ingredient":"FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE","trade_name":"ANORO ELLIPTA","family_id":"1f08573222a447518c92","publication_number":"US7498440B2","cleaned_patent_number":"7498440","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-04-27","publication_date":"2009-03-03","legal_status":"Expired"} US7498440B2 Molecular Formulation 03 Mar, 2009 Expired 27 Apr, 2025
{"application_id":"40406","ingredient":"FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE","trade_name":"ANORO ELLIPTA","family_id":"1f08573222a447518c92","publication_number":"US8309572B2","cleaned_patent_number":"8309572","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-04-27","publication_date":"2012-11-13","legal_status":"Granted"} US8309572B2 13 Nov, 2012 Granted 27 Apr, 2025
{"application_id":"40459","ingredient":"FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE","trade_name":"ANORO ELLIPTA","family_id":"1f08573222a447518c92","publication_number":"US8183257B2","cleaned_patent_number":"8183257","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-07-27","publication_date":"2012-05-22","legal_status":"Granted"} US8183257B2 22 May, 2012 Granted 27 Jul, 2025
{"application_id":"40471","ingredient":"FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE","trade_name":"ANORO ELLIPTA","family_id":"7886373716b541d8ad65","publication_number":"US7439393B2","cleaned_patent_number":"7439393","drug_product_flag":"-, Y","drug_substance_flag":"-, Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-11-21","publication_date":"2008-10-21","legal_status":"Expired"} US7439393B2 21 Oct, 2008 Expired 21 Nov, 2025
{"application_id":"2056","ingredient":"UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE","trade_name":"ANORO ELLIPTA","family_id":"7f771c722bec4e06a7d7","publication_number":"US8511304B2","cleaned_patent_number":"8511304","drug_product_flag":"-, Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-12-14","publication_date":"2013-08-20","legal_status":"Granted"} US8511304B2 20 Aug, 2013 Granted 14 Dec, 2027
{"application_id":"40457","ingredient":"FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE","trade_name":"ANORO ELLIPTA","family_id":"1f08573222a447518c92","publication_number":"US7488827B2","cleaned_patent_number":"7488827","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-12-18","publication_date":"2009-02-10","legal_status":"Granted"} US7488827B2 Molecular Formulation 10 Feb, 2009 Granted 18 Dec, 2027
{"application_id":"20211","ingredient":"FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE","trade_name":"TRELEGY ELLIPTA","family_id":"5bb2636d632f4e09acd5","publication_number":"US8534281B2","cleaned_patent_number":"8534281","drug_product_flag":"-, Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-09-08","publication_date":"2013-09-17","legal_status":"Granted"} US8534281B2 17 Sep, 2013 Granted 08 Sep, 2030
{"application_id":"36601","ingredient":"FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE","trade_name":"ANORO ELLIPTA","family_id":"771654a743d04583a35b","publication_number":"US9750726B2","cleaned_patent_number":"9750726","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-11-29","publication_date":"2017-09-05","legal_status":"Granted"} US9750726B2 Formulation 05 Sep, 2017 Granted 29 Nov, 2030
{"application_id":"36602","ingredient":"FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE","trade_name":"ANORO ELLIPTA","family_id":"62705b8f68754b9da6ea","publication_number":"US11090294B2","cleaned_patent_number":"11090294","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-11-29","publication_date":"2021-08-17","legal_status":"Granted"} US11090294B2 17 Aug, 2021 Granted 29 Nov, 2030
{"application_id":"2061","ingredient":"FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE","trade_name":"TRELEGY ELLIPTA","family_id":"f4b4a84415a84506bfb1","publication_number":"US8746242B2","cleaned_patent_number":"8746242","drug_product_flag":"-, Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-04-11","publication_date":"2014-06-10","legal_status":"Granted"} US8746242B2 10 Jun, 2014 Granted 11 Apr, 2031

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Umeclidinium Bromide

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.